PHILADELPHIA, PA — Vittoria Biotherapeutics, a leading biotechnology company, has announced its participation in the upcoming 65th American Society of Hematology (ASH) Annual Meeting, set to take place from December 9-12, 2023, in San Diego, California. The company will present abstracts authored by researchers at the University of Pennsylvania and a poster presentation authored by the Company.
The presentations are set to display data from the laboratory of Marco Ruella, M.D., Vittoria’s Scientific Founder and Chair of the Scientific Advisory Board. Dr. Ruella also serves as an assistant professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania (Penn) and is the Scientific Director of the Lymphoma Program at Penn Medicine’s Abramson Cancer Center.
The oral presentations will highlight recent data generated at Penn with Vittoria’s patented Senza5™ platform, a technology exclusively licensed from Penn to Vittoria, along with additional pipeline technologies. The Senza5 platform is a revolutionary approach to engineering cell therapies with improved anti-tumor efficacy, stemness, potency, and durability. It achieves this through gene-edited CD5 knockout and a proprietary five-day manufacturing process.
The first oral presentation, titled “Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies,” is scheduled for Saturday, December 9th at 10:45 am PST. Ruchi P. Patel, M.S., will be the presenter during the session “703. Cellular Immunotherapies: Basic and Translational: Overcoming Challenges in CAR-T Therapies Through Biological Insights.”
The second oral presentation, “Fratricide-Resistant Anti-CD2 Chimeric Antigen Receptor T-Cells with Endogenous CD2 Knockout Are Highly Effective Against T-Cell Neoplasms,” will be presented by Mathew G. Angelos, M.D., Ph.D. on Monday, December 11th at 3:15 pm PST during the session “703. Cellular Immunotherapies: Basic and Translational: Innovative T Cell Therapies for Unexplored Frontiers.”
Furthermore, a poster presentation titled “Senza5TM CART5: An Autologous CD5-Deleted Anti-CD5 CART Product with Enhanced Anti-T-Cell Lymphoma Activity” is scheduled for Sunday, December 10, 2023, at 6 pm PST during the session “703. Cellular Immunotherapies: Basic and Translational: Poster II.”
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.